Loading
Obesity / Tirzepatide / Endometrial Cancer · Phase EARLY_PHASE1 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned early-phase, single-arm window-of-opportunity trial examining whether tirzepatide reduces proliferation in endometrial cancer tissue between baseline biopsy and surgical resection. The study remains recruiting with no results yet posted. It is designed to test a mechanistic hypothesis about tirzepatide's effects on tumor microenvironment via insulin, lipid, and mTOR signaling pathways.
Early Phase 1, Interventional, Single Group, Open label, Treatment purpose. Endometrial Cancer, Obesity; Female; age from 18 Years. Intervention: endometrial carcinoma. n = 20. 1 site: United States.
This is a planned early-phase, single-arm window-of-opportunity trial examining whether tirzepatide reduces proliferation in endometrial cancer tissue between baseline biopsy and surgical resection. The study remains recruiting with no results yet posted. It is designed to test a mechanistic hypothesis about tirzepatide's effects on tumor microenvironment via insulin, lipid, and mTOR signaling pathways.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study will not guide current clinical practice until results are available. It represents early exploration of tirzepatide as a potential anti-tumor agent in obesity-driven endometrial cancer, but the small sample and window-of-opportunity design preclude any clinical recommendation at this stage.
This is an early-phase, uncontrolled window-of-opportunity study with a planned sample of 20 patients examining a mechanistic hypothesis in a pre-operative setting; no results are yet reported.
As stated by the source record.
Quoted from the source exactly as published.
This study will not guide current clinical practice until results are available. It represents early exploration of tirzepatide as a potential anti-tumor agent in obesity-driven endometrial cancer, but the small sample and window-of-opportunity design preclude any clinical recommendation at this stage.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07065552). This is a study registration, not published results. Lead sponsor: UNC Lineberger Comprehensive Cancer Center. Recruitment status: RECRUITING. Phase: EARLY_PHASE1. Study type: INTERVENTIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Endometrial Cancer, Obesity. Interventions: DRUG: Tirzepatide. Primary outcome measures: Change in Proliferation , Baseline - Up to 6 weeks. Brief summary: LCCC2415 examines the antiproliferative effect of tirzepatide on the endometrium of endometrial cancer (EC). This is a pre-operative window clinical study. Endometrial biopsy samples from patients before tirzepatide treatment will be compared to their post-intervention hysterectomy specimens. If archival tissue is unavailable, a fresh biopsy will be taken before tirzepatide treatment. Post-intervention tissue will be collected from the hysterectomy specimen. The hypothesis is that tirzepatide's anti-tumorigenic effects are due to both an improvement in the host's metabolic milieu (indirect effect) and a direct effect on the EC tumor microenvironment via the inter-related pathways of insulin, lipid, and mTOR signaling. Therefore, tirzepatide may be an innovative approach to effectively induce weight loss and inhibit tumor growth in EC, the most obesity-driven of all cancers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.